Study guide

1.15 Lynch Syndrome & Polyposis Syndromes

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

1.15 Lynch Syndrome & Polyposis Syndromes

Key Takeaways Explain This Topic AI

Lynch syndrome is autosomal dominant mismatch-repair (MMR) deficiency caused by MLH1, MSH2, MSH6, PMS2, or EPCAM deletion leading to MSH2 loss—distinct from polyposis-predominant syndromes

Tumor testing with MMR immunohistochemistry and/or MSI informs who needs germline Lynch evaluation; MLH1-absent tumors often need BRAF/MLH1 methylation workup for sporadic epigenetics

Amsterdam and Bethesda criteria are historical/clinical selection tools; they do not replace modern tumor testing and multi-gene germline strategies when indicated

Lynch extracolonic risks include endometrium, ovary, stomach, urothelial tract, small bowel, and others in a gene-specific pattern

FAP (APC, adenomatous polyposis) differs from MAP (biallelic MUTYH, recessive) and from Lynch (few polyps, MMR-driven cancers)—polyposis burden and inheritance separate these entities

Last updated: August 2026

1.15 Lynch Syndrome & Polyposis Syndromes

Quick Answer: Lynch = dominant MMR gene defect ( MLH1 , MSH2 , MSH6 , PMS2 , EPCAM ), few polyps, MSI-high/MMR-deficient tumors, extracolonic risks. FAP = APC adenomatous polyposis (dominant). MAP = biallelic MUTYH (recessive). Use IHC/MSI ± germline panels; do not confuse polyposis count with Lynch.

Colorectal hereditary cancer questions hinge on one skill: separate Lynch from polyposis syndromes using phenotype (polyp number), inheritance, and molecular pathway (MMR vs WNT/APC vs base-excision repair).

Lynch Syndrome: Features and Genes

Lynch syndrome (formerly HNPCC) is the most common inherited colorectal cancer predisposition syndrome. It is autosomal dominant and caused by pathogenic variants in DNA mismatch repair (MMR) genes, or by EPCAM deletions that epigenetically silence MSH2 .

  • Gene Pairing / notes Clinical flavor (high-level)
  • MLH1 Heterodimerizes with PMS2 Often higher colorectal penetrance among Lynch genes
  • MSH2 Heterodimerizes with MSH6; EPCAM deletions → MSH2 loss Classic Lynch; extracolonic spectrum prominent
  • MSH6 With MSH2 Sometimes later onset / attenuated colorectal pattern relative to MLH1 / MSH2
  • PMS2 With MLH1 Generally lower penetrance on average; still actionable
  • EPCAM 3′ deletions transcriptionally silence MSH2 Counsel as MSH2-related Lynch risk
  • Natural History and Tumor Spectrum

Lynch-associated colorectal cancers tend to be right-sided , may show mucinous or medullary histology, tumor-infiltrating lymphocytes, and microsatellite instability-high (MSI-H) / MMR-deficient phenotypes. Lifetime colorectal cancer risk is substantially elevated versus the general population, with gene-specific differences emphasized in NCCN Genetic/Familial High-Risk Assessment: Colorectal guidelines.

Extracolonic cancers (gene-weighted) commonly discussed in counseling:

  • Site Counseling relevance
  • Endometrium Often the sentinel cancer in women; gynecologic risk-reduction discussions
  • Ovary Elevated in Lynch—distinct management from BRCA RRSO scripts
  • Stomach / small bowel Upper GI surveillance considerations in selected patients
  • Urothelial (renal pelvis/ureter) Especially with MSH2 historically emphasized

Other Pancreas, brain (rare), sebaceous neoplasms (Muir-Torre spectrum), prostate discussions vary by gene/evidence

Muir-Torre refers to Lynch with sebaceous skin tumors; Turcot historically linked brain tumors with colorectal predisposition (MMR or APC contexts)—know the association labels without over-calling rare phenotypes.

MSI, IHC, and Diagnostic Strategy

Universal or near-universal tumor screening on colorectal (and often endometrial) cancers uses:

  • MMR immunohistochemistry (IHC) for MLH1, MSH2, MSH6, PMS2 protein presence/absence
  • and/or MSI testing (PCR/NGS) classifying MSI-H vs MSS

IHC pattern (simplified) Interpretation pathway

Loss of MLH1 ± PMS2 Consider sporadic MLH1 promoter methylation (± BRAF V600E in CRC) before or alongside germline testing

  • Loss of MSH2 ± MSH6 Strongly consider germline MSH2 / EPCAM (and related) evaluation
  • Isolated MSH6 or PMS2 loss Point toward those genes; technical pitfalls exist

All proteins present / MSS Lynch less likely for that tumor, but clinical judgment may still warrant germline panel if pedigree is striking

Constitutional MMR deficiency (CMMRD) is the rare biallelic childhood-onset phenotype—different counseling from heterozygous Lynch.

Amsterdam and Bethesda Criteria (Conceptual Use)

Tool Role on today’s exam

Amsterdam I/II Family-history rules of thumb (multiple CRC/Lynch cancers across generations, young ages)— sensitive for classic families , miss many real Lynch cases

Bethesda (revised) Flags tumors for MSI/IHC testing historically

Modern practice Tumor testing pathways + clinical criteria + multi-gene germline panels; criteria are aids , not gatekeepers that “rule out” Lynch

Exam tip: a vignette meeting Amsterdam supports suspicion, but normal IHC does not always end evaluation if clinical concern remains, and abnormal IHC needs methylation/BRAF triage when MLH1 is lost.

Surveillance and Risk Reduction (Lynch)

NCCN-style colorectal management for Lynch typically includes earlier and more frequent colonoscopy than average-risk schedules (often beginning in the 20s–early 30s depending on gene/family history, with shortened intervals). Additional considerations:

Endometrial symptom awareness ± screening approaches; discussion of hysterectomy ± BSO after childbearing for risk reduction in selected women

Aspirin chemoprevention discussions appear in evidence/guideline conversations—counsel as evolving/shared decision-making with clinicians

Immunotherapy relevance for MSI-H metastatic disease is an oncology management concept analogous to “results change treatment”

Polyposis Syndromes vs Lynch

Syndrome Gene / inheritance Polyp phenotype Key contrast with Lynch

Familial adenomatous polyposis (FAP) APC , AD Hundreds to thousands of colorectal adenomas (classic); attenuated FAP (AFAP) has fewer Polyposis-driven; CHRPE, desmoids, duodenal polyps, thyroid; childhood screening for classic FAP

MUTYH-associated polyposis (MAP) Biallelic MUTYH , AR Oligopolyposis to polyposis overlapping AFAP counts Recessive —parents usually unaffected; siblings at 25% risk; partners may need carrier testing

Lynch syndrome MMR genes / EPCAM , AD Usually few or no florid polyposis Cancer from MMR deficiency, not carpeting adenomas

Other NTHL1 , polymerase proofreading ( POLE / POLD1 ), SPS, etc. Variable Panel testing when phenotype unclear

FAP Management Anchors

Classic FAP often leads to discussion of colectomy timing in adolescence/young adulthood, lifelong endoscopic surveillance of remaining GI tract, and extracolonic surveillance (duodenum, thyroid, desmoid risk). Attenuated FAP may present later with fewer polyps—easily confused with MAP or Lynch if molecular testing is skipped.

MAP Counseling Anchors

Explain autosomal recessive inheritance clearly. Unaffected parents who are heterozygous carriers do not have the MAP phenotype themselves (heterozygous MUTYH modest risk nuances exist in literature but are not MAP). After biallelic identification, offer testing to siblings and discuss partner carrier screening for reproductive risk of affected children.

Diagnostic Strategy Algorithm (Board-Level)

Quantify polyp burden and ages of adenomas/cancers.

If polyposis → prioritize APC / MUTYH (and related polyposis genes) on a panel.

If Lynch-like cancers with few polyps → tumor IHC/MSI ± germline MMR panel.

Integrate pedigree (dominant vs possibly recessive).

Assign surveillance using current NCCN colorectal gene-specific tables.

Confusing Lynch with FAP is a classic miss: polyp count + molecular pathway prevent that error.